CV industry veteran succeeds Howlett as Lombard CEO
This article was originally published in Clinica
John Rush, a medical device industry veteran with particular experience in the cardiovascular sector, has succeeded Brian Howlett as CEO of UK stent graft developer Lombard Medical Technologies. Mr Rush, a US national, spent 10 years at SciMed Life Systems (which was bought by Boston Scientific in 1994) in various senior sales and marketing and management roles. He has been president and CEO of several small-cap companies, most recently at North American Scientific (NAS), where he led the firm's reorganisation and financial recovery. Mr Rush is expected to take Lombard through the next growth phase, as it expands commercialisation in Europe and secures FDA approval for its flagship Aorfix device. His predecessor, Mr Howlett, will be retiring after nearly four years at Lombard's helm, but will remain with the London firm as executive director until the end of March 2010 to oversee the transition.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.